Global Acitretin Market – Industry Trends and Forecast to 2031

Global Acitretin Market, By Type (Branded, Generics), Application (Psoriasis, Solid Organ Transplants, Darier Disease, Pityriasis Rubra Pilaris (PRP), Ichthyoses, Grover Disease (Transient Acantholytic Dermatosis), Lichen Planus, Lupus Erythematosus), Dosage (10mg, 25 mg, 50mg), End-Users (Dermatology Clinics, Specialty Clinics, Hospitals, Ambulatory Surgical Centre, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.

Acitretin Market Analysis and Size

Acitretin is a retinoid drug with similar activity to that of vitamin A. Acitretin is a water-soluble drug and is relatively less deposited in adipose tissue. FDA has approved Acitretin for psoriasis treatment involving generalized pustular psoriasis, pustular psoriasis localized, and severe plaque psoriasis, among others. It can be used as either monotherapy or combination therapy in conjunction with UVB (ultraviolet B), psoralen ultraviolet A (PUVA), cyclosporine, and also in combination with biological therapies.                            

Data Bridge Market Research analyzes that the global acitretin market which was USD 31.35 million in 2023, will reach USD 44.58 million by 2031, and is expected to undergo a CAGR of 11.20% during the forecast period. “Generics” dominates the type segment of the global acitretin market since growing demand for generics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Acitretin Market Scope and Segmentation

Market Definition

Acitretin, a retinoid, is a form of vitamin A. It is a second generation antipsoriatic drug. It is a prescription drug mainly applied to treat the psoriasis disease. It is long term use drug. It is found commonly in capsule type. It is not a principal cure for psoriasis and may result in relapse after medication termination. It may have side effects, such as severe congenital disabilities in pregnant females and severe liver problems.

Acitretin Market Dynamics

Drivers

• Increasing Prevalence of Psoriasis

The primary indication for acitretin is the treatment of severe psoriasis. As the prevalence of psoriasis continues to rise globally, the demand for effective treatment options, including acitretin, is likely to increase. Factors such as lifestyle changes, environmental factors, and genetic predisposition contribute to the growing incidence of psoriasis.

• Advancements in Psoriasis Treatment

Ongoing research and development activities in the field of dermatology and autoimmune diseases may lead to the introduction of new and improved treatment options for psoriasis. If acitretin demonstrates efficacy and safety compared to other treatment modalities, it could drive its adoption and market growth.

• Increasing Awareness and Diagnosis

Greater awareness about psoriasis and its impact on patients' quality of life may lead to increased diagnosis rates. As healthcare professionals and patients become more informed, there could be a higher demand for pharmacological interventions like acitretin, particularly in cases where other treatment options have proven ineffective or have undesirable side effects.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion of Indications

Investigating and obtaining approvals for new indications of acitretin beyond its current use in severe psoriasis could present a significant opportunity. Clinical trials exploring the efficacy of acitretin in treating related dermatological conditions or autoimmune disorders might open up new markets and increase the overall demand for the medication.

• Growing Collaborations and Partnerships

Collaborations with research institutions, academic centers, and other pharmaceutical companies can accelerate the development and commercialization of acitretin. Partnering with organizations working on complementary therapies or diagnostic tools for psoriasis may create synergies and provide a more comprehensive solution for patients. Additionally, collaborations can help share development costs and risks.

Restraints

• Stringent Regulatory Requirements

Regulatory requirements, especially concerning safety and efficacy, can pose challenges for the development, approval, and commercialization of acitretin. Meeting stringent regulatory standards may involve significant time and financial investments. Changes in regulatory guidelines or requirements can also impact the market dynamics, affecting the availability and accessibility of acitretin in certain regions.

• Generic Competition

As patents expire, the entry of generic versions of acitretin into the market can lead to increased competition and potential price erosion. Generic alternatives may offer cost savings for patients and healthcare systems, impacting the market share and revenue potential for the branded version of acitretin. Manufacturers may need to employ strategies to differentiate their product and maintain a competitive edge.

Challenges

• Side Effects and Safety Concerns

Acitretin, like many medications, is associated with side effects, including mucocutaneous effects, teratogenicity, and lipid metabolism abnormalities. Concerns related to these side effects may limit its use, especially in certain patient populations. Safety considerations and the need for careful monitoring may pose challenges to widespread adoption, particularly for individuals with reproductive potential.

• Availability of Alternative Therapies

The pharmaceutical landscape for psoriasis and related dermatological conditions offers a variety of treatment options, including topical agents, phototherapy, and biologic therapies. The availability of alternative and often more targeted treatments may impact the market for acitretin, as healthcare providers and patients may opt for therapies with potentially fewer side effects or faster onset of action.

This acitretin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acitretin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In May 2020, Allergen plc, a manufacturer of the acitretin drug was acquired and merged into AbbVie Inc. This helped to develop the service of production and distribution of the drug acitretin
• In April 2018, a Pediatric pharmacy advocacy group published about the unique preparation and delivery method for Acitretin for neonatal harlequin ichthyosis. No authors were found to be in conflict about the manuscripts, products, grants, and medication

Global Acitretin Market Scope

The acitretin market is segmented on the basis of product type, dose strength, distribution channel, application, and end-users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Branded
• Generics

Dose Strength

• 10mg
• 25mg
• 50mg

Application

• Psoriasis
• Solid Organ Transplants
• Darier Disease
• Pityriasis Rubra Pilaris (PRP)
• Ichthyoses
• Grover Disease (Transient Acantholytic Dermatosis)
• Lichen Planus
• Lupus Erythematosus

End-Users

• Dermatology clinics
• Specialty clinics
• Hospital Pharmacy
• Ambulatory Surgical Centre
• Others

Distribution Channel

• Direct Tende
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acitretin Market Regional Analysis/Insights

The acitretin market is analysed and market size insights and trends are provided by country, product type, dose strength, distribution channel, application, and end-users as referenced above.

The countries covered in the acitretin market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the global acitretin market because of the strong base of healthcare facilities, the strong presence of major players in the market, increased cases of surgical procedures among athletes, and the rising number of research activities in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The acitretin market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for acitretin market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acitretin market. The data is available for historic period 2010-2020.

Competitive Landscape and Acitretin Market Share Analysis

The acitretin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the acitretin market are:

• Biophore India Pharmaceuticals Pvt Ltd (India)
• Hangzhou Jinlan Pharmaceutical Technology Development Co., Ltd (China)
• Glopec International Inc. (Canada)
• Sun Pharma Industries Limited (India)
• Chongqing Huapont Pharmaceutical Co., Ltd. (China)
• SGPharma Pvt Ltd (India)
• AvKARE, LLC.(U.S.)
• Merck KGaA (Germany)
• Stiefel Laboratories Inc.(U.S.)
• Sionc Pharmaceuticals Pvt Ltd.(India)
• Prasco Laboratories (U.S.),
• Teva Pharmaceuticals USA, Inc. (U.S.)